Gene expression analysis of non-clear-cell renal cell carcinoma and clear-cell renal cell carcinoma kidney cancers

Data regarding the clinical outcomes of immune checkpoint inhibitor (ICI) therapy and profiles of the tumor immune microenvironment (TIME) in non-clear-cell renal cell carcinoma (nccRCC) remain limited. Here, we retrospectively compared the effectiveness profiles of first-line ICI combination therapy between patients with clear-cell RCC (ccRCC) and those with nccRCC. Overall design: RNA-seq of non-clear-cell renal cell carcinoma and clear-cell renal cell carcinoma kidney cancers Please note that cancer subtype information is provided in the "tissue" field. The treatment details and clinical outcomes of ICI therapy are presented in the associated publication.